Our Take
FDA sign-off on primary endpoints and 320-patient enrollment cap suggests Agomab is running a dose-finding study positioned to move fast to pivotal trial, not a proof-of-concept waiting for validation.
Why it matters
Fibrostenosing Crohn's disease has no approved drugs despite affecting nearly half of all Crohn's patients and driving surgery. A successful oral ALK5 inhibitor would address a genuine market gap and set the template for oral-first fibrotic disease trials.
Do this week
Gastroenterologists: flag fibrostenosing Crohn's patients now eligible for NOV-ERA enrollment (starting H2 2026) before off-label escalation decisions lock in your referral patterns.
Agomab cleared regulatory path for phase 2b dosing
Agomab Therapeutics announced the design of its NOV-ERA phase 2b study of ontunisertib, an oral ALK5 inhibitor for fibrostenosing Crohn's disease, after securing FDA agreement on trial endpoints. The company expects to begin patient dosing in the second half of 2026. The FDA has cleared the protocol; Health Canada and central US IRB approval are complete; and Clinical Trial Applications have been filed in the EU and Asia Pacific.
The randomized, double-blind, placebo-controlled, dose-ranging trial will enroll up to 320 adults with symptomatic fibrostenosing Crohn's disease (company-reported). Participants must have at least one non-passable ileal stricture confirmed by centrally read SES-CD scoring. Patients will receive one of three ontunisertib doses or placebo twice daily for 52 weeks, following a 6-week screening phase.
The primary efficacy endpoint is endoscopic passability at Week 24, measured by SES-CD narrowing score. Secondary endpoints include MRE (magnetic resonance enterography) changes, endoscopic response and remission, patient-reported outcomes, and time to stricture-related surgical events.
The target disease is genuinely unmet
Fibrostenosing Crohn's disease affects approximately 46% of Crohn's disease patients (per company statement) and currently has no approved pharmacological therapies. Fibrotic strictures in the intestinal tract cause obstructive symptoms that force dietary changes, trigger malnutrition, and drive surgical intervention. For gastroenterologists, the disease is managed either through diet restriction or endoscopic dilation (temporary) or resection surgery (permanent loss of bowel).
The FDA's agreement on endoscopic passability as a primary endpoint at Week 24 is deliberate. A non-invasive measure of stricture reversal or passability would be clinically meaningful and measurable within the trial timeline. This endpoint design suggests the FDA and Agomab both expect the drug to work quickly enough to show signal in the first half of the treatment period.
Philippe Wiesel, Chief Medical Officer, noted this is "the first Phase 2b study in FSCD," which underscores how little clinical-stage data exists in this population. The field has not yet converged on standard endpoints or dose ranges for ALK5 inhibitors in intestinal fibrosis.
What clinicians should watch
The 320-patient enrollment cap and dose-ranging structure suggest Agomab is designing for pivotal-trial readiness, not prolonged exploratory phases. If the trial shows dose-dependent efficacy on endoscopic passability by Week 24, the company will have a clear path to a large pivotal confirmatory trial and potentially accelerated regulatory timelines.
Gastroenterologists treating stricturing Crohn's disease should expect referral requests from investigators once enrollment opens in late 2026. Patients with symptomatic, non-passable ileal strictures confirmed on endoscopy will be eligible. The trial's exclusion criteria and imaging requirements will be published in the protocol, but the broad enrollment window suggests site selection will favor high-volume IBD centers with established endoscopy and MRE capabilities.
For now, the regulatory pathway is confirmed and the trial is operationally on track. The clinical question remains whether an oral ALK5 inhibitor can reverse or arrest fibrotic remodeling in the time window the FDA has accepted.